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Sickle cell anemia (SCA) is a genetic disease that affects mostly individuals of African
and/or Hispanic descent, with the majority of cases in sub-Saharan Africa. Individuals
with this disease show slowed growth, delayed sexual maturity, and poor immunologic
function. These complications could partly be explained by the state of undernutrition
associated with the disease. Proposed mechanism of undernutrition include protein
hypermetabolism, decreased dietary intake possibly from interleukin-6-related appetite
suppression, increased cardiac energy demand/expenditure, and increased red cell
turnover. All the above mechanisms manifest as increased resting energy expenditure.
Nutritional intervention utilizing single or multiple nutrient supplementation has led to
improved clinical outcome, growth, and sexual maturation. Studies are currently
underway to determine the best possible approach to applying nutritional intervention in
the management of SCA. Management of SCA will, of necessity, involve a nutritional
component, given the sociodemographic distribution of those most affected by the
disease, the ease of a nutritional approach, and the wider reach that such an approach
will embody.
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Background
Sickle cell anemia (SCA) is a genetic disease that results from the substitution of valine for glutamic
acid in the β-globin chain of the hemoglobin molecule (Pauling & Itano, 1949) and affects mostly
people of African or Hispanic descent. The consequence of this amino acid substitution is the
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formation of hemoglobin S (HbS). Under low oxygen tension and/or conditions of acidosis. HbS
precipitates and forms polymerized crystals called tactoids (hemoglobin polymers), which distort the
red blood cells (Ganong, 2003; Nelson & Cox, 2005). The resulting sickle-shaped red cells lose their
pliability and cannot navigate the small capillaries, become sticky, and adhere to the small veins,
small arteries, and other blood vessels causing vaso-occlusion (Aster, 2005; Bunn & Forget, 1977). In
addition, red blood cells homozygous for HbS (i.e., HbSS) are susceptible to premature destruction,
with a red blood cell life span of 8–25 days as opposed to 100–120 days for normal red blood cells
(Solanki, McCurdy, Cuttitta, & Schechter, 1988).
Sickle-cell anemia has a high prevalence throughout equatorial Africa; additionally, the genetic
defect is now known to be widespread in parts of Sicily and southern Italy, northern Greece,
southern Turkey, the Middle East, Saudi Arabia, much of central India, and the Americas
(Feldenzer, Mears, Burns, Natta, & Bank, 1979). This wide geographical distribution is thought to be
a result of the survival advantage, which the heterozygous genotype (HbAS) confers against malaria
infection, causing the genetic defect to persist in the population (Aidoo et al., 2002; Serjeant, 2001)
and the movement of people from Africa to other parts of the world. The burden of SCA is highest in
sub-Saharan Africa—especially in the West African country of Nigeria, where more than 130,000 (or
19–20:1000) children are born with the disease annually, and approximately 4 million people are
afflicted with the disease (Aliyu, Tumblin, & Kato, 2006; Olabode & Shokunbi, 2007; World Health
Organization, 1996; World Health Organization, 2006).
In the last few decades, more studies have documented the presence of micro- and macronutrient
deficiency among individuals with SCA and their possible association with immunologic (Bao et al.,
2008; Fraker, King, Laakko, & Vollmer, 2000; Heyman et al., 1985), nutritional (Gray et al., 1992;
Heyman et al., 1985), and growth (Serjeant, Singhal, & Hambleton, 2001; Zemel, Kawchak, OheneFrempong, Schall, & Stallings, 2007) abnormalities. Studies using direct measure of nutritional
status (Enwonwu & Lu, 1991; Gray et al., 1992; Kennedy et al., 2001; Leonard, Zemel, Kawchak,
Ohene-Frempong, & Virginia, 1998; Nelson et al., 2002), indirect assessment of nutritional status
(Borel, Buchowski, Turner, Goldstein, & Flakoll, 1998; Buchowski, de la Fuente, Flakoll, Chen, &
Turner, 2001; Buison et al., 2005; Henderson, Saavedra, & Dover, 1994; Serjeant et al., 2001; Silva &
Viana, 2005), and application of nutritional supplementation (Heyman et al., 1985; Prasad &
Cossack, 1984; Waugh, 2005; Williams et al., 2004) have established the association between SCA
and the presence of nutritional deficiency among patients with the disease. These studies showed
that although intake might be sufficient when measured against the recommended daily dietary
allowance for age and sex, it is still insufficient for the individual with SCA due to the increased
nutritional demand imposed by the disease. The result is the manifestation of malnutrition-like
features (Al-Saqladi, Cipolotti, Fijnvandraat, & Brabin, 2008; Hyacinth, Gee, & Hibbert, 2010;
Prasad, 1997).
This review seeks to draw attention to the link between this unapparent nutritional deficit and some
observed SCA-related complications. The purpose is to demonstrate that the pathogenesis of some
common SCA-associated complications might be related to caloric deficiency,; not caused by
inadequate intake, if measured by the standard for individuals without the disease. It further shows
that nutrient diversion for propagating and/or compensating for the disease and disease processes
might be responsible for the observed undernutrition-like feature of sickle cell disease. Finally, it
draws attention to the paucity of research and data on the interaction between nutrition and SCA in
humans and the need for further research to understand this relationship and its vital role in the
management of the disease.
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Sickle Cell Anemia and Undernutrition
Previous studies have hypothesized and documented that SCA leads to a state of undernutrition and
poor growth. A hypothesis that has gained traction is that of hypermetabolism. Simply put,
hypermetabolism is a state of increased caloric demand with a high rate of catabolism (nutrient
breakdown) compared with anabolism (nutrient buildup). In SCA, however, there is a shift toward
increased catabolism, leading to increased nutrient demand. Some studies have documented
hypermetabolic states among children with SCA (Borel et al., 1998; Hibbert et al., 2006). Hibbert
and colleagues (2006) reported that increased myocardial energy demand, along with increased
production of proinflammatory cytokines, is associated with increased resting energy expenditure
(REE), a surrogate marker of a state of hypermetabolism. Other investigators supported their
findings with the observation that, although individuals with SCA may consume diet deemed
adequate for a person without the disease, it might be insufficient to maintain normal body function
and metabolism, as reflected by delayed growth, slowed maturation, and low weight/height for age
(Henderson et al., 1994; Leonard et al., 1998; Silva & Viana, 2005; Zemel et al., 2007); thus, they are
in a state of increased energy demand. The shortened life span of sickle red blood cells compared
with normal red blood cells (Solanki et al., 1988) explains this finding. The increased destruction of
these cells creates a need for increased erythropoiesis (i.e., the process of making red blood cells),
which leads to increased protein turnover and thus increased energy demand (Borel et al., 1998;
Buchowski et al., 2001; Hibbert et al., 2006; Salman et al., 1996).
Furthermore, increased hemolysis results in decreased red cell count and anemia. As a compensatory
mechanism to maintain tissue oxygenation, the heart rate is increased, leading to increased
myocardial energy demand (Hibbert et al., 2006; Salman et al., 1996), with the net effect of an
increase in myocardial energy requirement and thus total energy requirement. As stated earlier, the
patient with SCA is in a state where catabolism exceeds anabolism, resulting in an energy
requirement that exceeds the apparently adequate nutrient intake in the absence of SCA. This
hypermetabolism has been documented as increased REE, which is a measure of the energy
consumption of an individual at rest. Studies show that individuals with SCA have a higher REE
compared with age- and sex-matched healthy controls (Akohoue et al., 2007; Barden et al., 2000;
Williams et al., 2004). This hypothesis thus posits that hypermetabolism leads to undernutrition
because it causes a diversion of nutrients from growth and other required body functions to support
the increased requirement for red cell production, increased myocardial energy demand due to
increased heart rate (a compensatory mechanism for anemia), and propagation of the state of chronic
subclinical inflammation reported among SCA patients (Akohoue et al., 2007; Hibbert et al., 2005;
Hibbert et al., 2006).
Another hypothesis states that reduced dietary intake exists in SCA patients, and that the state of
undernutrition is due wholly or in part to reduced dietary and energy intake (Fung et al., 2001), with
the adequacy of dietary intake decreasing as the individual gets older (Kawchak, Schall, Zemel,
Ohene-Frempong, & Stallings, 2007). This hypothesis has not gained as much traction as expected
because other studies have reported little to no difference between the dietary and energy intake of
children and adults with SCA compared with healthy non-SCA controls (Gray et al., 1992; Heyman
et al., 1985; Singhal, Parker, Linsell, & Serjeant, 2002). Despite this, some investigators have
posited that repeated ill health and hospitalization might affect the frequency of dietary and energy
intake (Hyacinth et al., 2010; Malinauskas et al., 2000). Furthermore, high levels of interleukin-6, a
circulating cytokine that is involved in inflammation and host immune defense, has been
documented to be associated with appetite suppression and, by extension, decreased dietary intake
in cancer patients (Rich et al., 2004; van Lettow, van der Meer, West, van Crevel, & Semba, 2005).
Elevated levels of this cytokine have also been reported in SCA patients (Hibbert et al., 2005) and
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transgenic SCA mice (Archer et al., 2008). It is believed that the elevated Interleukin-6 levels
observed in SCA patients might act to suppress their appetite, reducing dietary and energy intake.
In theory, SCA produces a form of protein energy malnutrition due not to poor intake, but to
increased energy demand.

Implication for Infection
Infections occur as a complication of SCA. These patients are particularly prone to infection with
encapsulated organisms because of the occurrence of autosplenectomy from repeated subclinical
splenic infarction associated with this disease (Aster, 2005). In addition, lower serum
immunoglobulin M levels, impaired opsonization, and sluggish alternative complement pathway
activation further increases susceptibility to other common infectious agents, such as Mycoplasma
pneumoniae, Salmonella typhimurium, Staphylococcus aureus, and Escherichia coli. Low serum
immunoglobulin level is a widely documented feature of malnutrition, thus malnutrition from
increased demand reported in patients with SCA can also account in part for their increased
susceptibility to infection (Fock, Vinolo, de Moura Sá Rocha, de Sá Rocha, & Borelli, 2007; Hughes et
al., 2009; Katona & Katona-Apte, 2008; Lesourd & Mazari, 1997), similar to what has been described
in children with non-SCA-associated malnutrition. These studies show that non-SCA children and
mouse models with protein energy malnutrition have impaired immune response to infection and/or
challenge with a component (lipopolysaccharide) of an infectious organism (Fock et al., 2007; Hughes
et al., 2009), as seen among children with malnutrition due to SCA. Serjeant (2005) reported that
septicemia among African SCA patients has been documented as being from organisms other than
Streptococcus pneumoniae, making traditional intervention to reduce mortality (Cummins,
Heuschkel, & Davies, 1991; Gaston et al., 1986; John et al., 1984) less effective. This increased
susceptibility to non-pneumococcal septicemia could be explained in part by the prevalence of
malnutrition in this region and a further increased prevalence among individuals with SCA. In
addition, the state of nutrient and energy deficiency caused by SCA could lead to increased
susceptibility, consequent upon a depressed immune system and response.
Studies in the last 2 decades using dietary supplement in patients (children and adults) with or
without SCA had reported—in addition to improved growth—a decrease in the incidence of infection
among the patients receiving these supplements (Bao et al., 2008; Heyman et al., 1985; Lesourd &
Mazari, 1997; Prasad et al., 2007; Salman et al., 1996). This evidence demonstrates a clear
association between the increased incidence of infection among patients with SCA and their “state of
[undernutrition].” Zinc, an often deficient nutrient in patients with SCA (Khan, Trottier, &
Naydenov, 2009; Leonard et al., 1998; Prasad, 2002), is also linked with increased risk for infection
when deficient, with supplementation resulting in a decrease in the incidence of infection (Bao et al.,
2008; Bhutta et al., 1999; Muskiet, Muskiet, Meiborg, & Schermer, 1991; Prasad et al., 2007;
Sazawal et al., 1998).

Implication for Growth and Maturational Abnormality
Growth and maturation is affected by SCA, resulting in growth retardation (Henderson et al., 1994;
Heyman et al., 1985) and slowed maturity (Serjeant et al., 2001). Children with SCA attain
maturational milestones such as menarche or adrenarche significantly later than their age- and sexmatched peers without SCA (Zemel et al., 2007). Their growth is also compromised as a result of
diversion of nutrient from buildup of tissues, in favor of the provision of energy for increased
myocardial demand, propagating inflammation and replenishing red blood cells, which are
constantly being hemolyzed (Hibbert et al., 2006). Studies using dietary supplementation in humans
with SCA (Heyman et al., 1985; Ohnishi, Ohnishi, & Ogunmola, 2000; Waugh, 2005; Williams et al.,
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2004; Zemel, Kawchak, Fung, Ohene-Frempong, & Stallings, 2002) and mouse models of human SCA
(Archer et al., 2008; Dasgupta, Hebbel, & Kaul, 2006; Fasipe, Ubawike, Eva, & Fabry, 2004; Kaul,
Zhang, Dasgupta, & Fabry, 2008) have reported various benefits of nutritional supplementation.
Delayed growth and maturation among individuals with SCA is associated with low plasma zinc
(Leonard et al., 1998), which is also associated with low levels of serum testosterone among males
(Prasad, 2008; Sandstead et al., 1967) and decreased pubertal development in general (Leonard et
al., 1998). Investigators have demonstrated that providing micronutrient supplements to individuals
with SCA led to improvement in growth and maturation by way of improved serum testosterone
levels. Parasad and Cossack (1984), as well as Zemel and colleagues (2002), demonstrated that
administering zinc supplements to growing children with SCA led to improvement in growth.
Supplementing other micronutrients like vitamin A (Schall, Zemel, Kawchak, Ohene-Frempong, &
Stallings, 2004), vitamin B, and magnesium (De Franceschi et al., 2000) resulted in clinical benefits
such as improved growth, decreased hospital emergency room visits, decreased frequency of pain
crisis, and reduced frequency of infection. It also led to improvement in muscle function, cognition,
and coordination; decreased inflammation; and improvement in antioxidant and anemia status.
These results, apart from demonstrating the benefits of nutrition in the management of SCA,
provide further support to the hypothesis that some SCA-associated complications have as much
nutritional underpinning as they do genetic.

Nutritional Intervention to Manage Sickle Cell Anemia
As earlier mentioned, several attempts have been and are being made to correct the nutritional
deficiency in SCA in order to improve growth (Heyman et al., 1985; Prasad & Cossack, 1984), body
composition (Zemel et al., 2002), and vascular and immune function (Kaul et al., 2008; Peranzoni et
al., 2008); compensate for the hypermetabolism associated with the disease (Williams et al., 2004);
and decrease inflammation (Archer et al., 2008; Dasgupta et al., 2006); among other improvements .
The great majority of these have been single-nutrient supplementation, with mixed results
(Hyacinth et al, 2010). A few have utilized a combination of nutrients, with really impressive results
even with a small sample size (Chan, 2000; Heyman et al., 1985; Ohnishi et al., 2000, Hibbert, Stiles,
Umeakunne, & Hyacinth, 2011). Some researchers believe that an approach that utilizes a
combination of nutrients (macro- and micronutrients) is likely to produce the best results (Chan,
2000; Ohnishi et al, 2000; Hyacinth et al., 2010). These investigators suggested that because
nutrient utilization in the body is a multistep process, with different nutrients feeding into the
process at various points, insufficient quantities of one component of this multistep process could
have a deleterious (Chan, Chow, & Chiu, 1999) effect on the entire body. Chan (2000) proposed that
an antioxidant will end up producing reactive oxygen species and, thus, oxidant stress if adequate
quantity of the antioxidant agent was not given ab initio. It was reasoned that in the absence of more
antioxidant nutrients, the oxidized form of the initially administered antioxidant ends up
propagating the oxidant damage it was administered to prevent.

Future Directions in Finding a Nutritional Remedy for
Sickle-Cell-Anemia–Associated Undernutrition
Currently, there are few ongoing pilot clinical trials in the United States with the aim of identifying
nutritional approaches to managing SCA, using a combination of macro and micro nutrients (Hibbert
et al, 2011) to provide additional calories in a low-bulk but high-calorie format that is appealing to
children. Some approaches use single macro or micro nutrients or a combination of micro nutrients.
An example is the recently published vitamin D study (Osunkwo et al, 2012) conducted at Emory
University. In this study, the investigators provided vitamin D supplement to children with SCA in
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order to prevent some of the pathologic bone changes observed in these patients. They reported an
increase in serum vitamin D and vitamin D precursor level among the supplemented group
compared with placebo. Additionally, they observed a decrease in the number of pain days and an
increase in the quality-of-life scores among the supplement compared with the placebo group. As
described by Ohnishi and colleagues (2000) and Chan (2000), a combined nutritional approach is
most appropriate because the combination of antioxidants exhibit a synergistic effect, and we expect
the same effect on improvement in health outcomes for individuals with SCA from an interaction
between macro and micro nutrients when administered at the same time by the same nutritional
supplement. With that in mind, our center designed and carried out a pilot clinical trial, which
adopted an approach that utilizes a combination of both micro and macro nutrients. The supplement
developed at our center will provide additional calories equal to 40% of that recommended for age
and sex to the normal daily dietary intake of the individual. This ensures that the extra caloric
requirement due to the pathological processes of the disease is adequately compensated for.
Additional funding is needed to enable further studies. Priority needs to be afforded this area of SCA
research, as it has the potential to address more than one problem (malnutrition in general,
maternal mortality, and child mortality), in addition to addressing the complications of sickle cell
disease. Multicenter studies that would enable the understanding of the relationship between
nutrition and SCA, in addition to informing patient care, can only be conducted with improved
funding. Although a lot has been learned from mouse models (Archer et al., 2008; Dasgupta et al.,
2006; Kaul et al., 2008; Capers et al., 2010; Romero, Suzuka, Nagel, & Fabry, 2002), our recent work
(yet to be published) indicates that the dietary requirements are different. For example, while a
normal balanced human diet contains 12–15% of calories from protein, that of mice contains about
20% of calories from protein. Furthermore, mice with SCA have other hematological and pathological
features that are different from what has been described among humans with SCA (Manci et al.,
2006). This necessitates additional funding to enable more robust human studies, although it should
still be informed by data from studies using mouse models.
Sickle-cell-anemia–associated complications such as stroke and acute chest syndrome are being
managed using chronic packed red blood cell transfusion and hydroxyurea. Results from the Stroke
Prevention in Sickle Cell Anemia (STOP) trial, Hydroxyurea to Prevent Organ Damage in Children
With Sickle Cell Anemia (also known as the Pediatric Hydroxyurea Phase III, or BABY-HUG,
clinical trial), and Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG or HUG-KIDS) clinical
trial all suggest these approaches alone are unable to promote growth and maturity to any
appreciable level (Adams et al., 1998; Thompson et al., 2010; Wang et al., 2002). It is the position of
the authors, however, that if these interventions were coupled with additional caloric
supplementation, the results might be different. This is because neither packed red blood cell
transfusion nor hydroxyurea provide any appreciable decrease in caloric need or provide any
appreciable amount of added calories for patients with sickle cell disease.
Finally, the importance of finding a nutritional remedy lies in the fact that currently available
approaches for managing sickle cell disease are either too expensive and not readily accessible (e.g.,
bone marrow transplantation) or have side effects, such as alloimmunization and iron overload in the
case of blood transfusion and potential risk for malignancy in the case of hydroxyurea. Furthermore,
it will be essential for more studies to adopt a nutritional approach as a part of the management
modality for SCA in the light of the fact that more than two-thirds of the patients with SCA live in
areas of the world with low socioeconomic status and have little to no means of accessing the
aforementioned management approaches.
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Conclusion
Sickle cell anemia still remains a devastating global disease that reduces the life expectancy of
millions of children of African descent. It is a serious cause of health disparity between countries and
between races within the same country. Many complications associated with the disease have a
nutritional underpinning. Addressing this problem requires further—and larger—multicenter
studies that will enable the development of a tailored daily dietary requirement for individuals
(children, adults, and pregnant women) with SCA. Additionally, multinational collaboration is
required in order to identify the differences in caloric requirement that might exist between
individuals with SCA residing in developed, developing, and emerging-economy countries. Finally, a
nutritional approach for the management of this disease holds a lot of promise for improving the
clinical outcome, quality of life, and future prospects of those with SCA.
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